Jason Riffe, DO
Family Medicine · Broken Arrow, OKNPI 1487817698
Payments from drug & device makers
Across 361 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$662
- AbbVie$634
- Bayer$484
- Lilly USA, LLC$418
- Boehringer Ingelheim$313
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,124100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $1,043 |
| Pfizer | 38 | $662 |
| AbbVie(2 entities) | 39 | $634 |
| Bayer | 29 | $484 |
| Lilly USA, LLC | 26 | $418 |
| Boehringer Ingelheim | 20 | $313 |
| GSK | 18 | $284 |
| Merck | 24 | $251 |
| Exact Sciences | 14 | $217 |
| Abbott | 10 | $185 |
| Novo Nordisk | 10 | $170 |
| Amgen | 10 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $147 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $118 |
| Eisai Inc. | 5 | $106 |
| Johnson & Johnson | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Novartis | 3 | $65 |
| Astellas Pharma US Inc | 4 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| Dexcom, Inc. | 2 | $41 |
| Radius Health, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| Nalpropion Pharmaceuticals LLC | 3 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $28 |
| Medtronic | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Biogen | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Alk-abello, Inc | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,148 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $122,372 |
| EliquisApixaban | 83 | $96,536 |
| JanuviaSitagliptin Phosphate | 70 | $74,642 |
| JardianceEmpagliflozin | 41 | $56,720 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $52,548 |
| XareltoRivaroxaban | 51 | $41,570 |
| MounjaroTirzepatide | 35 | $33,717 |
| FarxigaDapagliflozin Propanediol | 32 | $31,660 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $27,074 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $20,380 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $18,308 |
| LinzessLinaclotide | 24 | $16,073 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $16,022 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $15,447 |
| Atorvastatin Calcium | 548 | $14,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $170 | $122,372118 claims |
| PfizerEliquis | $662 | $96,53683 claims |
| MerckJanuvia, Janumet | $251 | $90,09088 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $284 | $75,673104 claims |
| Boehringer IngelheimJardiance | $313 | $56,72041 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,043 | $47,68259 claims |
| Johnson & JohnsonXarelto | $87 | $41,57051 claims |
| Lilly USA, LLCMounjaro | $418 | $33,71735 claims |
| AbbVieLinzess, Viberzi | $634 | $26,32435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Broken Arrow
- James CampbellBroken Arrow$35K
- Corey ChamnessBroken Arrow$20K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.